RenovoRx, Inc. (RNXT) earnings
RNXT earnings moved a median of -3.04% by the close. Quarterly and annual RNXT reports and results, each read against the price at its own news timestamp. Back to the RNXT overview →
24 measured RNXT earnings events.
Where these RNXT earnings landedvs 24 measured RNXT earnings reactions
| Middle 50% of RNXT earnings reactions | -4.90% to +2.97% |
|---|---|
| Median reaction (to close) | -3.04% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 RNXT earnings events with a measured close landed between -4.90% and +2.97%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q RenovoRx, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.76% | +10.24% | |
| RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth | Press release | +5.36% | +12.50% | |
| RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET | Press release | +0.00% | -1.31% | |
| Form 10-K/A RenovoRx, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.21% | -5.64% | |
| Form 10-Q RenovoRx, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.74% | -4.65% | |
| RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter | Press release | -1.74% | -4.65% | |
| RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET | Press release | +0.61% | +1.35% | |
| Form 10-K RenovoRx, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.21% | -7.34% | |
| RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET | Press release | +0.00% | -2.54% | |
| Form 10-Q RenovoRx, Inc. For: Jun 30 | SEC filing · Form 10-Q | -5.38% | -4.45% | |
| RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review | Press release | -5.38% | -4.45% | |
| RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET | Press release | +3.49% | +8.53% | |
| Form 10-Q RenovoRx, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.90% | +6.31% | |
| RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights | Press release | +0.90% | +6.31% | |
| RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET | Press release | — | +3.13% | |
| Form 10-K RenovoRx, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.02% | -2.02% | |
| Form NT 10-K RenovoRx, Inc. For: Dec 31 | SEC filing · Form NT | +0.02% | -2.02% | |
| RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights | Press release | +2.65% | -3.54% | |
| Form 10-Q RenovoRx, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.65% | -3.54% | |
| Form 10-Q RenovoRx, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -5.88% | |
| Form 10-Q RenovoRx, Inc. For: Mar 31 | SEC filing · Form 10-Q | +5.11% | +2.92% | |
| Form 10-K RenovoRx, Inc. For: Dec 31 | SEC filing · Form 10-K | — | -7.46% | |
| RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights | Press release | — | -29.02% | |
| Form 10-Q RenovoRx, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | -29.02% |
Keep exploring
More RNXT: analyst actions → · SEC filings → · RNXT overview →